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Background to the debate: In a 2007 article in PLoS
Medicine [10], Holger J. Schu ¨nemann and colleagues
described a new process used by the World Health
Organization for rapidly developing clinical manage-
ment guidelines in emergency situations. These situa-
tions include outbreaks of emerging infectious diseases.
The authors discussed how they developed such a
‘‘rapid advice’’ guideline for the pharmacological
management of avian influenza A (H5N1) virus infection.
The guideline recommends giving the antiviral drug
oseltamivir at a dose of 75 mg twice daily for five days.
In this Debate, Nicholas White argues that such dosing
is inadequate, Robert Webster and Elena Govorkova say
that combination antiviral therapy should be used, and
Tim Uyeki reminds us that clinical care of patients with
H5N1 entails much more than antiviral treatment.
These issues may also apply to therapy of patients
hospitalized with severe disease due to novel swine-
origin influenza A (H1N1) virus infection.
Nicholas White’s Viewpoint: Common Sense
Argues That High Doses of Oseltamivir Should Be
Used
Developing Treatment Guidelines for Potentially Lethal
Infections
Rapidly fatal infections need urgent treatment with optimum
doses of appropriate antimicrobials. Such doses should ideally
produce maximum effects as quickly as possible, and provide the
greatest differential between lives saved and lives lost because of
toxicity. If the antimicrobial drug is not eliminated rapidly, a
loading dose should be given to provide therapeutic concentrations
as soon as possible.
This dosing strategy for rapidly fatal infections contrasts with
dose recommendations for uncomplicated infections—such rec-
ommendations are aimed at lower microorganism burdens, where
rapidity of action is less important and adverse effects are of
greater significance. In other words the risk-benefit trade-off,
commonly termed the therapeutic ratio, is different in severe and
uncomplicated infections.
This difference has important implications for treatment
guidelines. According to the World Health Organization
(WHO): ‘‘Guidelines are formal advisory statements which should
be robust enough to meet the unique circumstances and
constraints of the specific situation to which they are being
applied’’ [1]. Treatment guidelines are best when they rest on a
sound and consistent evidence base [1,2]. Randomised clinical
trials (RCTs) are considered to provide the best evidence. But what
if the evidence from controlled trials is insufficient, or there simply
isn’t any? Guidance and specific recommendations are still
necessary. Inadequate initial treatment of life-threatening infec-
tions has serious consequences. Therefore, common sense argues
for recommending higher doses for such infections, at the expense
of increased toxicity, to avoid any possibility of under-dosing those
patients with unusual pharmacokinetics and more resistant
organisms. If intravenous administration is not possible, absorp-
tion from the gut or intramuscular injection site may be
compromised in the most seriously ill, arguing again for higher
doses.
In this context of critical uncertainty, and against a background
of concerns over liability and consequent risk aversion, physicians
often seem more worried about the risks of adverse effects than of
under-dosing, even though antimicrobial adverse effects are rarely
fatal. Seldom is an infectious disease death ascribed to adminis-
tration of inadequate doses.
Treatment Guidelines for H5N1 Influenza
H5N1 influenza is regarded by many as the greatest threat to
human health and national security [3]. Fortunately human
infections are still rare, but this rarity also means that there are no
published RCTs of treatment. The oral viral neuraminidase
inhibitor oseltamivir (Tamiflu) is considered the drug of choice
[4,5]. There is no parenteral formulation. H5N1 influenza
replicates more rapidly than seasonal influenza viruses [4,5],
reaching much greater viral burdens than do other human
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tently exceeds 50%, which puts H5N1 influenza amongst the most
lethal of human infections.
Experimental studies with H5N1 viruses in animal models
suggest that high doses and long courses of neuraminidase
inhibitors provide optimal treatment [7,8]. Despite this
evidence, a ‘‘rigorous and transparent’’ process, led by
WHO, to develop treatment guidelines for H5N1 influenza
has recommended an adult dose of 75 mg twice daily for five
days. This is the ‘‘standard’’ dose regimen for uncomplicated
seasonal influenza [9,10]. If absorbed well, this 75 mg dose
might provide maximal neuraminidase inhibition at the sites of
infection in all patients seriously ill with H5N1 influenza. In
other words it might be enough, but the truth is that we just
do not know. The concentration-effect relationship in patients
has not been characterised. Oseltamivir doses of up to
1,000 mg have been given to volunteers. High doses of
oseltamivir are reasonably well tolerated in humans, and there
is experimental evidence to suggest they could be more
effective [5,7,8,11,12].
There seems little to gain and everything to lose by using a
low dose of this potentially life-saving drug in a highly lethal
infection. The ‘‘evidence-based approach’’ (Grading of Recom-
mendations Assessment, Development and Evaluation or
GRADE; see http://www.gradeworkinggroup.org/), now con-
sidered ‘‘state of the art’’ for guideline development [1,13,14],
has been constrained by lack of RCT evidence on higher doses
of oseltamivir. In recent years a hierarchy of the quality of
evidence has been increasingly promoted, particularly for the
formulation of guidelines. ‘‘Hierarchies place randomised
controlled trials (RCTs) at their summit, with various forms of
observational studies nestling in the foothills,’’ says Rawlins [15],
but information from observational studies and other foothill
inhabitants (experimental investigations, analogy with similar
conditions and processes, pathological and pharmacological
understanding and reasoning, and a derived assessment of risks
and benefits) is also valuable. In the case of pandemic influenza,
the GRADE process has resulted in a dose recommendation for
H5N1 influenza that could be too low.
Using All the Evidence To Assess the Risks and Benefits
In contrast to the GRADE approach, a ‘‘mechanism-based’’
approach, incorporating current understanding of this lethal
disease and of antimicrobial pharmacology, and assessing the
risks and benefits, would lead to initial use of the highest
oseltamivir doses considered to have a low risk of major toxicity
in H5N1 influenza. This fundamental difference in analytical and
deductive approaches is analogous to the frequentist versus
Bayesian debate in statistics. Rawlins has recently articulated the
important limitations of relying too much upon evidence from
RCTs and has argued cogently for greater use of a Bayesian
approach in decision making on recommendations for therapeutic
interventions [15]. Different approaches to the same problem may
yield different results initially, although as evidence accrues, results
of the two approaches tend to converge.
The current approach to guideline development may be too
restrictive. Where there is little or no direct evidence from RCTs,
the current ‘‘evidence-based approach’’ to treatment guidelines
certainly needs reconsideration. In the absence of direct evidence
on dosing in a rapidly lethal infection, basic precepts of
antimicrobial pharmacology (‘‘Bayesian priors’’) and common
sense argue that the highest possible dose of an antimicrobial
should be used, at least initially, until evidence becomes available
to inform the recommendation.
Robert Webster and Elena Govorkova’s
Viewpoint: Effective H5N1 Influenza Management
Calls for the Adoption of a Multidrug Approach
Nature has again sent a message to scientists and public health
officials concerned with the current pharmacological treatment of
humans with a potential pandemic influenza virus. The message is
loud and clear that the strategy of relying on single anti-influenza
drug treatment is wrong. The rapid emergence of seasonal
influenza A (H1N1) viruses resistant to oseltamivir in Scandinavia
at the end of 2007 (where little or no anti-influenza drugs are used)
was unexpected [16]. These resistant viruses contain the
His274Tyr neuraminidase mutation and have remarkable fitness;
they spread globally in less than a year [17]. While the oseltamivir-
resistant influenza A (H1N1) viruses are still susceptible to the
neuraminidase inhibitor zanamivir (Relenza), it would be foolish to
continue being complacent and rely on monotherapy. Influenza
viruses have a segmented RNA genome that is error-prone during
replication and lacks proofreading mechanisms. This fundamental
property of influenza viruses guarantees that resistant variants will
emerge. Such resistance may occur spontaneously and naturally
(without drug intervention) but would be facilitated by the use of
single-agent chemotherapy with oseltamivir alone.
Extensive experience treating human immunodeficiency virus
(HIV) clearly showed the futility of single-agent antiviral therapy;
drug-resistant HIV strains emerged almost immediately in patients
receiving monotherapy [18,19]. The subsequent, successful
management of HIV with multidrug combinations of highly
active antiretroviral therapy (HAART) has enabled thousands of
patients to control their disease and live productive lives. HAART
targets multiple functions of the virus (i.e., reverse transcription,
protein synthesis, attachment, and entry) [20]. These lessons from
HIV must be applied to influenza.
The reason given for continuation of anti-influenza monother-
apy is that drugs targeting specific viral functions are not available;
this partial truth is simply an excuse that impedes our progress.
Currently, two classes of anti-influenza drugs are available: the
adamantanes (amantadine and rimantadine) and the neuramini-
dase inhibitors (oseltamivir and zanamivir). Amantadine resistance
predominates among seasonal influenza A (H3N2) viruses, and the
ineffectiveness of the adamantanes against influenza B viruses
makes their use pointless. In fact, their use is counterproductive,
because it facilitates selection of resistance.
Can we use available therapies to minimize the impact of H5N1
influenza outbreaks in humans? There are at least ten clades of
H5N1 influenza viruses [21]. Two dominant clades affect humans:
clades 1 and 2.1 viruses are often adamantane-resistant, and
representatives of clades 2.2 and 2.3 are adamantane-susceptible
[4]. Clades 1 and 2 are susceptible to neuraminidase inhibitors,
and the current WHO guidelines suggest that clinicians administer
a double dose of oseltamivir to severely ill patients because of the
drug’s uncertain absorption and the high disease mortality [22].
However, given the ease with which naturally occurring
oseltamivir-resistant H1N1 viruses emerge and become dominant,
N1 neuraminidase and H5N1 viruses will probably have a similar
fate. Thus, we must consider a multidrug approach to managing
patients with H5N1.
Combination chemotherapy for influenza is supported by data
from animal models. Combinations of oseltamivir and amantadine
inhibited H5N1 virus replication in the lungs and brains of
infected mice, whereas monotherapy was only partially effective
[23]. The combination of oseltamivir and ribavirin (a polymerase
inhibitor, although not approved for influenza in most countries)
showed additive efficacy against clades 1 and 2, though efficacy
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combination of oseltamivir and ribavirin is far from optimal, but
many approaches to combination therapy for influenza are in the
pipeline: (1) development of additional neuraminidase inhibitors or
parenteral drug formulations; (2) new antiviral targets, including
the polymerase and hemagglutinin molecule and attachment
inhibition; (3) modulation of overexuberant innate host response;
(4) antibody-mediated therapy; and (5) combined antiviral and
vaccine strategies. Currently under development is the neuramin-
idase inhibitor peramivir, which has three chemical groups that
interact with the active-site residues of neuraminidase, resulting in
tight binding and a slow rate of dissociation.
The development of intravenous and intramuscular drug
formulations will also provide advantages against systemically
replicating H5N1 influenza viruses. Long-acting, single-dose
inhaled neuraminidase inhibitors will probably be available in a
few years. Other potential targets for drug development include
the surface protein hemagglutinin and polymerase inhibitors. T-
705, a potent inhibitor of viral RNA polymerase, is active against
neuraminidase inhibitor-resistant and amantadine-resistant virus-
es. New treatments such as immunomodulatory drugs that
potentially control immune system-mediated tissue damage will
require strong experimental evidence before adoption.
Combination chemotherapy consisting of anti-influenza drugs
and inflammation inhibitors (e.g., celecoxib and mesalazine) was
recently reported as a promising approach to control H5N1
infection in mice [25]. Another exciting recent discovery is the
ability of the type II diabetes drug pioglitazone to modulate
tissue-damaging compounds of the innate immune response
without compromising T cell-mediated viral clearance [26]. The
passive administration of humanized monoclonal antibodies to
H5 hemagglutinin in mice [27,28] and the creation of
comprehensive influenza antibody libraries from survivors of
the H5N1 avian influenza [29] have also provided encouraging
data.
Many virus and host factors influence the outcome of H5N1
disease progression. Therefore multiple anti-influenza drugs must
be used to effectively treat and prevent the spread of infection
(Figure 1). Results from our experiments [23,24] suggest that a
combination therapy approach guards against the emergence of
resistant strains. Thus, we propose that combinations of
adamantanes and neuraminidase inhibitors be immediately
introduced, ribavirin use be further evaluated, and clinical trials
of T-705 proceed with urgency.
Tim Uyeki’s Viewpoint: Clinical Management of
Patients with H5N1 Is Challenging—Data Are
Needed To Guide Clinicians
The emergence of a new respiratory infection that can cause
rapid severe outcomes, including death, presents major challenges
for identifying optimal clinical management and treatment. For
example, early in the severe acute respiratory syndrome (SARS)
epidemic, oral or intravenous ribavirin was administered to
patients with SARS on the assumption that this antiviral
medication would have activity against a suspected respiratory
viral pathogen. Unfortunately, it is unclear if ribavirin was
beneficial for treatment of patients with SARS, and hemolytic
anemia occurred in some treated patients [30,31]. Methylpred-
nisolone was also administered widely to patients with SARS, and
higher doses were associated with avascular necrosis among
survivors [32,33]. To date, no definitive treatment exists for
human infection with SARS-associated coronavirus (SARS-CoV),
and there are still challenges in collecting data from controlled
clinical treatment trials of novel pathogens [34].
Since 1997, sporadic human infection with highly pathogenic
avian influenza A (HPAI) H5N1 virus has caused illness in more
than 440 persons in 15 countries [35–37], with mortality
consistently higher than 60% among reported cases [37]. In
contrast with the emergence of human infection with SARS-CoV,
a pathogen with no previously documented treatment, HPAI
H5N1 virus is an influenza A virus, and antiviral medications with
documented in vitro activity and clinical benefit for related
susceptible seasonal influenza A subtype viruses have existed for
years. However, most published clinical studies of antiviral
treatment for human infection with seasonal influenza A viruses
have been conducted among otherwise healthy outpatients with
uncomplicated influenza in which early treatment (less than
Figure 1. A multidrug approach to the management of influenza. HA, hemagglutinin; IFN, interferon; LANI, long-acting neuraminidase
inhibitor; NA, neuraminidase; siRNA, small interfering RNA.
doi:10.1371/journal.pmed.1000091.g001
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been only two published retrospective studies of treatment among
hospitalized elderly [42,43].
In the absence of controlled clinical treatment trial data for
patients with HPAI H5N1 virus infection, what is the best
guidance based upon available data? Is it valid to extrapolate data
from early treatment of seasonal influenza A virus infection,
largely for uncomplicated influenza among outpatients, to
hospitalized patients with severe HPAI H5N1 disease, especially
when the pathogenesis may be different [4,6]? In 2006, WHO
convened a panel to assess the available evidence and issued
guidance for antiviral treatment and chemoprophylaxis of H5N1
virus infection [9,10]. Limited data suggest higher H5N1 patient
survival with earlier or any oseltamivir treatment (standard dosing
for five days) compared to late or no treatment [4,44,45]. WHO
also issued guidance recommending consideration of higher
oseltamivir dosing and longer duration of treatment, especially
for patients with late clinical presentation and severe disease
[4,22], and recommended against routine corticosteroid treatment
[4,22]. To date, clinical data on H5N1 antiviral treatment to guide
clinicians are limited.
Multiple challenges confront the clinician caring for a patient
with suspected or confirmed H5N1 virus infection. First, HPAI
H5N1 virus is dynamic and a ‘‘moving target.’’ H5N1 virus strains
continue to evolve into multiple genotypes and antigenically
distinct clades and subclades, and at least ten clades of H5N1 virus
strains have been identified to date [4]. Virus strains in four clades,
including three subclades of clade 2 viruses, have infected humans
to date [4].
Furthermore, these strains have different in vitro antiviral
susceptibility profiles. Resistance to the adamantane antivirals
(amantadine, rimantadine) is widespread among clade 2.1 and
clade 1 H5N1 viruses [4]. Decreased susceptibility to oseltamivir
was identified in viral isolates from patients with H5N1 clade 2.3.4
and clade 2.2 before antiviral treatment was initiated, suggesting
that strains circulating among poultry had reduced oseltamivir
susceptibility [46,47]. It is unknown whether higher dosing has
clinical effectiveness against H5N1 virus strains exhibiting reduced
in vitro oseltamivir susceptibility. Development of resistance to
H5N1 virus during oseltamivir treatment has been shown in clade
1 virus strains, including during early treatment [48], and was
reported in a patient who had received oseltamivir chemopro-
phylaxis [49].
While human data on combination antiviral treatment are very
limited [50], animal data support a benefit of combination
antiviral treatment over monotherapy for H5N1 virus infection
[23,24]. Indeed, WHO recommended consideration of combina-
tion antiviral treatment with an adamantane plus a neuraminidase
inhibitor for H5N1 patients infected with susceptible virus strains
[4,22].
The biggest challenge for physicians to initiating antiviral
treatment is to identify H5N1 virus-infected patients early, before
severe disease progression has occurred. Nonspecific signs and
symptoms hinder clinical recognition of early H5N1 disease in
most patients [4,51], and some H5N1 patients do not always have
identified exposure to H5N1 virus [44,52]. Fortunately, H5N1
virus infection remains rare worldwide, so the only way to detect
early infection is to test a huge number of suspected cases early, in
which very few will have H5N1 virus infection [53]. Additionally,
wide availability of an accurate, simple, inexpensive, rapid, point
of care test (which does not exist currently), as well as antiviral
medications, would be needed at health care facilities in countries
with H5N1 poultry outbreaks. However, H5N1 virus may not
always be detectable in an upper respiratory tract specimen from
an infected patient during early illness [4].
Currently, most H5N1 virus-infected patients are identified and
hospitalized about four to six days after illness onset when they
have severe disease [4,44,45,50,54]. Given that the pathogenesis
appears to include high H5N1 viral replication in the lower
respiratory tract driving cytokine dysregulation [4,6], other
therapy besides late antiviral treatment or higher dosing may be
needed. H5N1 patients with diarrhea may require higher dosing of
antivirals, and documentation of viral dissemination (viremia,
cerebrospinal fluid, brain, intestinal tract) in fatal cases suggests
that intravenous treatment may be needed [4,6,55]. High-dose
oseltamivir administration via oral gastric tube has been shown to
achieve high plasma levels in two ventilated patients with H5N1
[56].
In a very small number of severely ill patients with H5N1,
antivirals and immunotherapy were administered [50,57,58]. The
source of the immunotherapy was convalescent plasma from
patients with H5N1 who survived or from a participant in an
H5N1 vaccine clinical trial [50,57,58]. All three severely ill
immunotherapy recipients recovered fully. While these results are
compelling, this immunotherapy was uncontrolled, few patients
were treated, and other therapies, including antivirals, were
administered. Clearly, additional research on such therapy is
needed. But these initial results do raise questions about whether
even in severely ill patients, antiviral treatment and administration
of neutralizing antibodies can decrease H5N1 viral load rapidly
and dampen cytokine dysregulation, allowing pulmonary recovery.
Clinical care of patients with H5N1 entails much more than
antiviral treatment. Management of complications such as acute
respiratory distress syndrome, hypoxemia, pleural effusions,
pneumothoraces, disseminated intravascular coagulation, renal
dysfunction, and multi-organ disease requires excellent intensive
care [4,51]. It is possible that improving and standardizing optimal
intensive care unit (ICU) care for patients with H5N1, including
ensuring adequate oxygen delivery and optimizing ventilator
management, might result in lower mortality—even among
patients who are admitted with severe disease. Collection of
comprehensive clinical data detailing how patients with H5N1 are
cared for, and training in standard ICU care and ventilator
management of patients with H5N1 for clinicians in H5N1-
affected countries, might lead to improved clinical management
with higher patient survival. Infection control must be emphasized
among health care workers and family caregivers [59–61]. In the
setting of a disease with very high mortality, with no available
controlled human clinical data to guide clinicians, in which most
patients present with severe disease, a number of combined
strategies should be considered for therapy of H5N1 patients.
These include both pharmacological strategies (combination
antiviral treatment, anti-inflammatory agents, and immunothera-
py), and non-pharmacological strategies (standardization of
optimal ventilator and fluid management, especially for acute
respiratory distress syndrome, and management of other compli-
cations). Collection of detailed clinical data is needed to inform
optimal management of patients with H5N1, with defined clinical
and virological outcomes. Similar issues confront clinicians
treating patients hospitalized with severe lower respiratory tract
disease due to novel swine-origin influenza A (H1N1) virus
infection (currently resistant to adamantane antivirals) [62].
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